- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02310724
TODAY2 Phase 2 Follow-up (T2P2)
29 de julio de 2021 actualizado por: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Long-term Post-Intervention Follow-up of the TODAY Cohort (Treatment Options for Type 2 Diabetes in Youth and Adolescents)
The primary objective of T2P2 is to track the progression of T2D and related comorbidities and complications in the TODAY cohort as they transition to young adulthood. We hypothesize that:
- Youth-onset type 2 diabetes (T2D) will progress rapidly and result in high rates of diabetes-related medical complications and comorbidities.
- The rapid rate of progression is related to increased insulin resistance characteristic of puberty, worse β-cell function, degree of glycemic control, control of non-glycemic factors, and obesity itself.
Descripción general del estudio
Tipo de estudio
De observación
Inscripción (Actual)
517
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Denver Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University School of Medicine Department of Pediatrics
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02215
- Joslin Diabetes Center
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos, 63110
- Washington University
-
Saint Louis, Missouri, Estados Unidos, 63104
- Saint Louis University
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Naomi Berrie Diabetes Center
-
Syracuse, New York, Estados Unidos, 13210
- SUNY Upstate New York University
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Western Reserve University Rainbow Babies and Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Science Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Children's Hospital of Pittsburgh
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine
-
San Antonio, Texas, Estados Unidos, 78229
- University of Texas Health Sciences Center
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
15 años y mayores (Niño, Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
All subjects randomized into the TODAY study are eligible to participate in T2P2.
There are no additional inclusion or exclusions criteria for participation in T2P2.
Descripción
Inclusion Criteria:
- Participated in TODAY clinical trial.
Exclusion Criteria:
-
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
---|---|
TODAY cohort
All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2.
The study performs long-term observation only and administers no treatment, care, or management.
|
This protocol is observation only and involves no intervention, care, treatment, or management.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
diabetic retinopathy
Periodo de tiempo: year 4
|
a microvascular complication determined by fundus photography
|
year 4
|
microalbuminuria
Periodo de tiempo: every 12 months
|
a microvascular complication determined by urine albumin excretion >= 30 mg/day
|
every 12 months
|
overt diabetic nephropathy
Periodo de tiempo: every 12 months
|
a microvascular complication determined by glomerular filtration rate < 70 mL/min/1.73m2
|
every 12 months
|
peripheral diabetic neuropathy
Periodo de tiempo: every 12 months
|
a microvascular complication defined as the presence of Michigan Neuropathy Screening Instrument (MNSI) exam score >2 and <8 out of 10 appropriate responses to the Semmes-Weinstein monofilament (SW-MF) in either foot.
|
every 12 months
|
cardiac function
Periodo de tiempo: year 2
|
a macrovascular (cardiovascular) risk indicator determined by echocardiogram
|
year 2
|
arterial stiffness
Periodo de tiempo: year 5
|
a macrovascular (cardiovascular) risk indicator determined by pulse wave velocity
|
year 5
|
cardiovascular risk lipid values
Periodo de tiempo: every 12 months
|
a macrovascular (cardiovascular) risk indicator determined by abnormal lipid value for LDL (>= 130 mg/dL) or triglycerides (>= 300 mg/dL)
|
every 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
glycemic control
Periodo de tiempo: every 12 months
|
determined by HbA1c (annual)
|
every 12 months
|
psychological disorder
Periodo de tiempo: every 12 months
|
determined by scores on the following participant self-report standard surveys: (a) the Beck Depression Inventory II (BDI-II), (b) the Patient Health Questionnaire (PHQ) scales for somatic symptoms, anxiety, and alcohol use; participants are also interviewed about emotional or mental health problems involving referral, treatment, or hospitalization, and psychiatric diagnoses made by a non-study source that can be confirmed according to standard study criteria from acquired medical records are also recorded
|
every 12 months
|
body composition
Periodo de tiempo: every 12 months
|
determined by body mass index (BMI) computed from physical measurements of height and weight
|
every 12 months
|
insulin sensitivity and beta cell function
Periodo de tiempo: participant years 6 and 9 from baseline
|
determined by oral glucose tolerance test (at 6 and 9 years from randomization) to derive measures of insulin sensitivity (1/insulin0), insulin secretion (ΔC-peptide30-0/Δglucose30-0, Δinsulin30-0/Δglucose30-0 if not on insulin), and the oral disposition index (oDI = insulin sensitivity x insulin secretion)
|
participant years 6 and 9 from baseline
|
eating disorder
Periodo de tiempo: every 12 months
|
determined by score on participant self report questionnaire Eating Disorder Diagnostic Scale (EDDS)
|
every 12 months
|
health-related quality of life
Periodo de tiempo: every 12 months
|
determined by score on the participant self report questionnaire Pediatric Quality of Life Inventory version 4.0 with age-specific versions for teen (13-18), young adult (19-25), and adult (≥26)
|
every 12 months
|
blood pressure
Periodo de tiempo: every 12 months
|
determined by collection of blood pressure
|
every 12 months
|
sleep function
Periodo de tiempo: years 2-3
|
determined by scores on standard questionnaires and in-lab polysomnogram
|
years 2-3
|
life stress
Periodo de tiempo: every 12 months
|
determined by participant self report questionnaire based on the Yeaworth Adolescent Life Change Event Scale
|
every 12 months
|
healthcare usage
Periodo de tiempo: every 6 months
|
determined by participant self report about visits, referrals, treatments, tests, and procedures related to healthcare
|
every 6 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Investigadores
- Investigador principal: Sonia Caprio, MD, Yale University
- Investigador principal: Silva Arslanian, MD, University of Pittsburgh
- Silla de estudio: Philip S Zeitler, MD PhD, University of Colorado Denver Children's Hospital
- Investigador principal: Jeanie B Tryggestad, MD, University of Oklahoma Health Science Center
- Investigador principal: Mitchell E Geffner, MD, Children's Hospital Los Angeles
- Investigador principal: Robin S Goland, MD, Columbia University Naomi Berrie Diabetes Center
- Investigador principal: Lorraine L Katz, MD, Children's Hospital of Philadelphia
- Investigador principal: Lori MB Laffel, MD, Joslin Diabetes Center
- Investigador principal: Jane L Lynch, MD, University of Texas Health Sciences Center at San Antonio
- Investigador principal: Siripoom V McKay, MD, Baylor College of Medicine
- Investigador principal: Rose Gubitosi-Klug, MD, Case Western Reserve University Rainbow Babies and Children's Hospital
- Investigador principal: Sherida E Tollefsen, MD, St. Louis University
- Investigador principal: Ruth S Weinstock, MD PhD, SUNY Upstate Medical Center
- Investigador principal: Neil H White, MD, Washington University School of Medicine
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Trief PM, Uschner D, Tung M, Marcus MD, Rayas M, MacLeish S, Farrell R, Keady J, Chao L, Weinstock RS. Diabetes Distress in Young Adults With Youth-Onset Type 2 Diabetes: TODAY2 Study Results. Diabetes Care. 2022 Mar 1;45(3):529-537. doi: 10.2337/dc21-1689.
- TODAY Study Group; Shah RD, Braffett BH, Tryggestad JB, Hughan KS, Dhaliwal R, Nadeau KJ, Levitt Katz LE, Gidding SS. Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes. J Diabetes Complications. 2022 Mar;36(3):108123. doi: 10.1016/j.jdiacomp.2021.108123. Epub 2022 Jan 3.
- TODAY Study Group. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care. 2020 Oct;43(10):2469-2477. doi: 10.2337/dc20-0760. Epub 2020 Aug 10.
- TODAY Study Group. Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus: The TODAY Follow-Up Study. Circ Heart Fail. 2020 Jun;13(6):e006685. doi: 10.1161/CIRCHEARTFAILURE.119.006685. Epub 2020 Jun 5.
- TODAY Study Group; Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021 Jul 29;385(5):416-426. doi: 10.1056/NEJMoa2100165.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de marzo de 2014
Finalización primaria (Actual)
17 de enero de 2020
Finalización del estudio (Actual)
17 de enero de 2020
Fechas de registro del estudio
Enviado por primera vez
18 de junio de 2014
Primero enviado que cumplió con los criterios de control de calidad
4 de diciembre de 2014
Publicado por primera vez (Estimar)
8 de diciembre de 2014
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de agosto de 2021
Última actualización enviada que cumplió con los criterios de control de calidad
29 de julio de 2021
Última verificación
1 de julio de 2021
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- DK61230-T2P2
- U01DK061230 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
The TODAY/TODAY2 Study Group engages in a number of methods to disseminate and share resources.
- Findings are reported in manuscripts and presentations.
- An active Ancillary Studies Committee reviews proposals to access the study cohort, the central database, and stored biospecimens.
- Materials from the TODAY lifestyle intervention program and the standard diabetes education manual for adolescents developed by study experts are made available for public access on the website https://today.bsc.gwu.edu/web/today/home.
- The study group adheres to the policies of the NIDDK Central Repositories to make data available to other scientific investigators. A TODAY2 de-identified database will be prepared and transferred along with excess stored biospecimens. Appropriate informed consent is required to transfer stored biospecimens.
- TODAY establishes collaborative arrangements to work with other federally funded study groups.
Marco de tiempo para compartir IPD
Data will be prepared and provided to the NIDDK Data Repository in early 2022
Criterios de acceso compartido de IPD
Currently with approval of the Ancillary Studies Committee and after 2022 as determined by the NIDDK Data Repository
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes tipo 2
-
Jin-Hee AhnAsan Medical CenterDesconocidoAmplificación del gen HER-2 | Sobreexpresión de proteína HER-2
-
The University of Tennessee, KnoxvilleTerminadoProfesores de Matemáticas (Grados 2-8) | Estudiantes de Matemáticas (Grados 2-8)Estados Unidos
-
PowderMedTerminado
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.DesconocidoTumor solido | Amplificación del gen HER-2 | Mutación del gen HER2 | Sobreexpresión de proteína HER-2Porcelana
-
Argorna Pharmaceuticals Co., LTDTerminado
-
Argorna Pharmaceuticals Co., LTDTerminado
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Activo, no reclutando
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Activo, no reclutando
-
Arcturus Therapeutics, Inc.Terminado
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsTerminado
Ensayos clínicos sobre TODAY cohort
-
Istituto Clinico HumanitasReclutamientoCáncer colonrectal | CirugíaItalia